spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  CSL Plasma 

 HSMN NewsFeed - 19 Apr 2021
Haemonetics Provides Update On U.S. Plasma Business
Devices
 HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Dec 2019
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Apr 2019
CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA(R) [Alpha1-Proteinase Inhibitor (Human)]
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 16 Mar 2018
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Aug 2017
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Jul 2017
HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2015
U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2015
FDA Approves New Dosing Option for CSL Behring's Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 4 Oct 2012
Study Supports Efficacy, Safety of Hizentra(R) in Japanese Patients with Primary Immunodeficiency Disease
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 15 Mar 2012
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Biopharmaceuticals Surgery
 HSMN NewsFeed - 3 Jan 2012
CSL Behring Receives FDA Approval of Expanded Label on Berinert(R) for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Oct 2010
Privigen(R) Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2010
Data Support Hizentra(R) Efficacy, Safety After Dose-Equivalent Switch in Adult and Pediatric Patients with Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2010
Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin(R) as First-Line Therapy for Primary Immunodeficiency
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2009
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Biopharmaceuticals FDA
Return to NewsFeed  
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!